Nemaura Medical Strengthens Manufacturing Team in Preparation for SugarBEAT® Commercial Launch.
August 28 2018 - 4:00AM
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ:
NMRD), a medical technology company
developing sugarBEAT® as a non-invasive glucose trending
device for use by persons with diabetes and pre-diabetics
today announced it has expanded its
manufacturing team with the appointments of Omar
Farooq as Project Manager and David McLachlan
as a Project Director, both of whom bring substantial
expertise to the company.
Dr. Faz Chowdhury CEO of Nemaura Medical
commented, ‘We are delighted to have Omar and David join
our team, and are confident in their combined
ability to support and guide the company’s manufacturing
scale-up from initial launch in the United Kingdom, to a
global launch in multiple territories.’
These appointments are intended to
supplement Nemaura’s existing team of
engineers, scientists and outsourced service
providers as preparations continue for launch
of sugarBEAT® in the coming months.
Omar is a chartered chemical engineer with 20 years
of regulated industry experience across the full
engineering lifecycle, including design, construction,
commissioning, operation and process optimisation.
David will be directing the manufacturing and
qualification strategy across multiple sites,
to facilitate seamless transition into
commercial launch and subsequently the scale up to
support launches in multiple territories worldwide.
David has an honours degree from Herriot
Watt University, Edinburgh and over 25 years of
experience in the healthcare industry. Most
recently, he played a pivotal role in creating the
manufacturing capability for the launch of a new blood glucose
monitoring strip for a leading test strip
manufacturer. This
work included developing business cases for
various manufacturing options, vendor selection and approval,
and enhancing process throughput.
About Nemaura Medical, Inc.
Nemaura Medical Inc. (NASDAQ: NMRD), is a medical
technology company developing sugarBEAT® as a non-invasive,
affordable and flexible glucose trending device for use by persons
with diabetes and pre-diabetics.
SugarBEAT® consists of a daily disposable adhesive skin-patch
connected to a rechargeable transmitter, with an app displaying
glucose readings at five minute intervals over periods up to 24
hours.
SugarBEAT® can additionally be used by insulin using persons
with diabetes as an adjunctive glucose monitoring device when
calibrated by a finger stick reading.
For more information
visit:www.NemauraMedical.comwww.sugarBEAT.com
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical
facts, and may constitute forward-looking statements that are based
on current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Nemaura
Medical’s ongoing studies, including the safety and efficacy
of Nemaura Medical’s sugarBEAT® system, the failure of future
development and preliminary marketing efforts, Nemaura Medical’s
ability to secure additional commercial partnering arrangements,
risks and uncertainties relating to Nemaura Medical and its
partners’ ability to develop, market and sell sugarBEAT®, the
availability of substantial additional equity or debt capital to
support its research, development and product commercialization
activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and
strategies, including those plans and strategies related to
sugarBEAT®. These and other risks and uncertainties are identified
and described in more detail in Nemaura Medical’s filings with the
Securities and Exchange Commission, including, without limitation,
its Annual Report on Form 10-K for the current year, its Quarterly
Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura
Medical undertakes no obligation to publicly update or revise any
forward-looking statements.
Contacts
Nemaura Medical Inc.Bashir TimolChief Business
Officerbashir.timol@nemauramedical.com
orThe Ruth GroupLee Roth646-536-7012lroth@theruthgroup.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024